GSK Upbeat on Solid Results - Interviews with CEO and CFO

GSK Upbeat on Solid Results - Interviews with CEO and CFO
 
LONDON, February 7, 2012 /PRNewswire via COMTEX/ -- In an online video interview with MerchantCantos, GlaxoSmithKline CEO Sir Andrew Witty talks about the pharmaceutical group's special dividend, solid results and why the company is so well positioned to continue to deliver.

Sir Andrew said "adversity isn't all downside for everybody" and that the market offered opportunities for companies who had strengthened and had changed their exposure to places of growth.

"This is a time where we should feel optimistic. And certainly at GSK we do feel optimistic. We feel like are moving into a new era for the company and we now need to focus on absolute disciplined execution to make sure that we take advantage of all of the opportunities that we've worked so hard to try and create for ourselves."

CFO Simon Dingemans admitted there had been some margin pressure in Q4 but that he expected margins to improve gradually. "We expect only a very gradual increase in operating margin, and by that I mean a few tens of basis points and more in 2013 and further thereafter."

The interviews and transcripts are available now on http://www.cantos.com/company/GlaxoSmithKline .

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email [email protected]

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.